In Vivo PK

       The PK experiment of FcRn transgenic mice is a method used to study the pharmacokinetics of therapeutic antibody drugs in vivo. FcRn (neonatal Fc receptor) is an important protein that can bind to IgG antibodies, thereby affecting the clearance rate of antibodies in the body. By using a humanized FcRn transgenic mouse model, researchers can more accurately predict the pharmacokinetic properties of antibody drugs in the human body, providing important basis for drug development.  

       This experimental method can reduce the risk of developing therapeutic antibody drugs while reducing reliance on non-human primate models. It provides an ideal solution for obtaining reliable, precise, and predictable PK clinically data quickly and efficiently at the most economical cost, empowering innovative transformation for in vivo efficacy research and optimization design of therapeutic antibody candidate molecules.